ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
NUSAP1 Recruits DAXX to Suppress HIF-Driven Triple-Negative Breast Cancer Progression.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- DDX21 Promotes Breast Cancer Growth and Metastasis via Stimulating RNAPII Elongation During Hypoxia.MedComm · 2026Article
- NUSAP1 Recruits DAXX to Suppress HIF-Driven Triple-Negative Breast Cancer Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Activation of endogenous retroviruses in tumor cells and their immunomodulatory mechanisms: from molecular basis to clinical translation.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Nucleolar and spindle-associated protein 1 (NUSAP1) is critical for cancer progression. However, its function in cancers is context-dependent, and emerging evidence indicates that NUSAP1 possesses tumor suppressor functions, although the underlying mechanisms remain uncharted. In this study, NUSAP1 depletion is found to significantly increases the proliferation, migration, and invasion of triple-negative breast cancer (TNBC) cells in vitro and promotes TNBC progression in vivo, suggesting that NUSAP1 is a tumor suppressor in TNBC. Mechanistically, NUSAP1 bridges HIFα and the transcriptional repressor death domain-associated protein (DAXX) through its microtubule-associated domain (MAD) to recruit the methyltransferase SETDB1, thereby attenuating HIF transcriptional activity and the expression of its target genes by depositing the H3K9me3 repressive mark on hypoxia response elements (HREs). Intriguingly, an engineered MAD of NUSAP1, designated as Tumor Suppressor-MAD (TS-MAD), is developed, which effectively abrogates HIF transcriptional activity by bridging the DAXX-HIF interaction, consequently inhibiting HIF-driven TNBC progression. Moreover, NUSAP1 is identified as a novel HIF-repressed gene in TNBC cells, and its expression level shows a negative correlation with clinical outcomes in TNBC patients. These findings establish an HIF-NUSAP1 double-negative feedback loop in TNBC and validate TS-MAD as a potential therapeutic strategy for HIF-driven cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.